Roche 4625358019 CoaguChek XS PT Test Strip, Pack of 24

Product Information

New oral anticoagulants are an alternative to vitamin K antagonists and can be administered to reduce the risk of thrombosis or stroke. The new oral anticoagulants have fewer food and drug interactions than vitamin K antagonists and they do not involve therapeutic monitoring. However, they may be unsuitable for some people such as people with mechanical heart valves, people with renal or liver dysfunction and those taking concurrent drugs that cannot be taken with the new oral anticoagulants. NICE technology appraisal guidance recommends the use of 3 new oral anticoagulants: apixaban, rivaroxaban and dabigatran etexilate, for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. From 4th April, our friendly, expert team at Williams Medical will be responsible for all sales and training of the CoaguChek®

Note that this document is not NICE's final guidance on the CoaguChek XS system and the INRatio2 PT/INR monitor. The recommendations in section 1 may change after consultation.Heneghan, C., Alonso-Coello, P., Garcia-Alamino, J.M., Perera, R., Meats, E., Glasziou, P. (2006). Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 367, 404–411 exclusive self-testing or self-management compared with standard monitoring in primary and secondary care

The results indicated that over a 10-year period, introducing self-monitoring would reduce the proportion of people experiencing a thromboembolic event by 2.5%, whilst slightly increasing the proportion having a major haemorrhagic event by 1.4%.

exclusive primary or secondary care clinic testing compared with self-monitoring in primary and secondary care Approximately 47% of people with atrial fibrillation currently receive vitamin K antagonist therapy. It is estimated that a further 30% of people with atrial fibrillation could receive this therapy but currently do not. People with atrial fibrillation are at a 5–6 times greater risk of stroke, with 12,500 strokes directly attributable to atrial fibrillation occurring every year in the UK. Treatment with warfarin reduces this risk by 50–70%. Heart valve disease Vice Chair, Diagnostics Advisory Committee and Consultant in Public Health Medicine, PHG Foundation, Cambridge and UK Genetic Testing Network The Committee discussed the different versions of the CoaguChek systems. The Committee heard from clinical specialists and the manufacturer that changes had been made to the different versions to improve reliability and accuracy. The Committee concluded that results from the CoaguChek XS system were likely to be at least as good as those obtained from trials in which previous versions of the system were used. The Committee also noted that 4 trials investigated the use of the CoaguChek XS system. The Committee concluded that it was appropriate to pool the results of trials using different versions of the CoaguChek system. Value": "The CoaguChek XS System is intended for use by professional healthcare providers for quantitative prothrombin time testing for the monitoring of warfarin therapy. The CoaguChek XS System uses fresh capillary or nonanticoagulated venous whole blood.",